Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations
Jun Wang(Shenzhen Bao'an District People's Hospital), Baocheng Wang(Hong Kong University of Science and Technology), Shengxiang Ren(Tongji University), Lu Si(Peking University), Jianchun Duan(Chinese Academy of Medical Sciences & Peking Union Medical College), Chunxia Su(Tongji University), Yunpeng Yang(Sun Yat-sen University), Ye Guo(Army Medical University), Haifeng Qin(Third Affiliated Hospital of Guangzhou Medical University), Bicheng Zhang(University of Electronic Science and Technology of China), Quanli Gao(Zhengzhou University), Jiuwei Cui(Jilin University), Zhenzhou Yang(Dalian Medical University), Shukui Qin(81th Hospital of PLA), Xiaorong Dong(Union Hospital), Junli Xue(Shanghai East Hospital), Yue Lu(Tiangong University), Mengxia Li(Soochow University), Wensheng Qiu(Qingdao University), Zheng Zhao(HKUST Shenzhen Research Institute), Huijuan Wang(Beijing Chao-Yang Hospital, Capital Medical University), Jin Li(Shanghai Cancer Institute), Lian Liu(Qilu Hospital of Shandong University), Ling Peng(Guangzhou University of Chinese Medicine), Hongmei Zhang(Xijing Hospital), Wenfeng Li(Qingdao University), Yutao Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Li Zhang(Peking University), Rongcheng Luo(Hebei Medical University), Jun Guo(Hebei Medical University), Zhiyong He(Albert Einstein College of Medicine), Jianguo Sun(Army Medical University), Junping Zhang(Shanxi Academy of Medical Sciences), Xiufeng Liu(Sichuan University), Xianbao Zhan(Second Military Medical University), Xiubao Ren(Tianjin Medical University Cancer Institute and Hospital), Dingwei Ye(Fudan University), Qian Chu(Tongji Hospital), Yongsheng Wang(Lanzhou University of Technology), Yun Fan(Chinese Academy of Medical Sciences & Peking Union Medical College), Gen Lin(Fujian Medical University), Jun Ma(Harbin Institute of Petroleum), Bo Zhu(Huaian First People’s Hospital)
Cited by 10
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Monodispersed Colloidal Spheres: Old Materials with New Applications
|Advanced Materials|2000|2k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k